Eli Lilly announces $27-billion US expansion: To add 13,000 jobs and new manufacturing sites
Eli Lilly & Co has unveiled plans to expand its US manufacturing operations with a $27-billion investment in four new plants set to open in 2025. This brings Lilly’s total US investment to over $50 billion since 2020.
Trump-Modi Meet
The mega MIGA, MAGA plans of India's Modi and US' Trump
Trump says India has more tariffs than others
Trump's 'golden rule' for imposing reciprocal tariffs
The expansion is expected to generate 13,000 new jobs, including 3,000 permanent positions in engineering, science, and operations, alongside 10,000 construction roles to build the new facilities, according to MarketWatch.
Lilly’s Chief Executive, David A. Ricks, described the move as a bold step to meet the growing demand for safe, high-quality medicines approved by the FDA.
Focus on key drugs and supply chain resilience
Three of the four new sites will focus on active pharmaceutical ingredient (API) production, reshoring small-molecule chemical synthesis, and enhancing Lilly’s supply chain. The fourth facility will specialise in developing future injectable therapies, including Mounjaro (for Type 2 diabetes) and Zepbound (for weight loss).
Lilly is in discussions with several US states to finalise plant locations, with a proposal deadline set for March 12.
Artificial Intelligence(AI)
Java Programming with ChatGPT: Learn using Generative AI
By — Metla Sudha Sekhar, IT Specialist and Developer
Artificial Intelligence(AI)
Basics of Generative AI: Unveiling Tomorrows Innovations
By — Metla Sudha Sekhar, IT Specialist and Developer
Artific
